Prime Medicine Q3 net loss narrows

Prime Medicine

07/11/2025 12:14

Overview

Prime Medicine Q3 net loss narrows to $50.6 mln from $52.5 mln last year

Operating expenses rise due to increased R&D costs, offset by lower G&A expenses

Company advances liver-targeted programs, clinical data expected in 2027

Outlook

Prime Medicine expects to file IND/CTA for WD in H1 2027

Initial clinical data for WD and AATD expected in 2027

Result Drivers

R&D expenses were $44.0 million for the three months ended September 30, 2025, as compared to $40.3 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.32
Q3 Net Income
-$50.58 mln
Q3 Income from Operations
-$53.97 mln
Q3 Operating Expenses
$55.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Prime Medicine Inc is $7.00, about 40.3% above its November 6 closing price of $4.18

Press Release: ID:nGNX2xSMqr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)